United Therapeutics (UTHR) Tops Q4 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results
February 22, 2017 6:00 AM ESTSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2016.
"Our annual 2016 financial results reflect continued growth as net revenues reached $1.6 billion and earnings exceeded $700 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "These financial results strengthen our ability to develop and advance our growing product pipeline, which includes seven phase III programs and multiple second generation Remodulin drug delivery systems."
Key financial highlights include (in... More
